8578

Acetyl-CoA Carboxylase 2 (D5B9) Rabbit



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 280	Source/Isotype: Rabbit IgG	UniProt ID: #000763	Entrez-Gene Id: 32
Product Usage Information	e	Application Western Blotting Immunoprecipitation			Dilution 1:1000 1:50	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		Acetyl-CoA Carboxylase 2 (D5B9) Rabbit mAb recognizes endogenous levels of total acetyl-CoA carboxylase 2 protein and does not cross-react acetyl-CoA carboxylase 1.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val1400 of human acetyl-CoA carboxylase 2 protein.				
Background		Acetyl-CoA carboxylase (ACC) catalyzes the carboxylation of acetyl-CoA to malonyl-CoA (1). It is the key enzyme in the biosynthesis and oxidation of fatty acids (1). In rodents, the 265 kDa ACC1 (ACCα) form is primarily expressed in lipogenic tissues, while 280 kDa ACC2 (ACCβ) is the main isoform in oxidative tissues (1,2). However, in humans, ACC2 is the predominant isoform in both lipogenic and oxidative tissues (1,2). Phosphorylation by AMPK at Ser79 or by PKA at Ser1200 inhibits the enzymatic activity of ACC (3). ACC is a potential target of anti-obesity drugs (4,5).				
Background References		1. Castle, J.C. et al. (2009) <i>PLoS One</i> 4, e4369. 2. Kreuz, S. et al. (2009) <i>Diabetes Metab Res Rev</i> 25, 577-86. 3. Ha, J. et al. (1994) <i>J Biol Chem</i> 269, 22162-8. 4. Abu-Elheiga, L. et al. (2001) <i>Science</i> 291, 2613-6. 5. Levert, K.L. et al. (2002) <i>J Biol Chem</i> 277, 16347-50.				
Species Reactivity		Species reactivity is determined by testing in at least one approved application (e.g., western blot).				
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting IP: Immunoprecipitation				
Cross-Reactivity Key		H: Human				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks a more information.	are the property of t	heir respective owners.	Visit cellsignal.com	/trademarks for
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
		Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in				

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not

sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.